Smac-mimetics are emerging as promising anti-
cancer agents and are being evaluated in clinical trials for a variety of
malignancies. Smac-mimetics can induce TNF production from a subset of
tumor cells and simultaneously sensitize them to TNF-induced apoptosis. However, TNF derived from other cellular sources, such as cytotoxic lymphocytes (CLs) within the
tumor, may also contribute to the anti-
tumor activity of SMs. Here, we show that CD8+ T cells and NK cells potently kill
tumor cells in the presence of the SM,
birinapant. Enhanced CL killing occurred through TNF secretion upon
tumor antigen recognition or NK-activating receptor
ligation. Importantly, the
perforin/
granzyme route to CL-mediated
tumor cell killing was dispensable for the efficacy of
birinapant, emphasizing the importance of the TNF-mediated apoptosis pathway. Time-lapse microscopy revealed that
birinapant sensitized
tumor cells to apoptosis as bystanders and to membrane-bound TNF delivered to
tumor cells within the immunological synapse. Furthermore, PD-L1 expression on
tumor cells suppressed
antigen-driven TNF production by CD8+ T cells, which could be antagonized through PD-1 blockade. Importantly, the elevated levels of TNF produced upon PD-1 blockade further enhanced
tumor cell killing when combined with
birinapant. The combined anti-
tumor activity of IAP antagonism and PD-1 blockade occurred independently of
perforin-mediated
tumor cell death. Taken together, we identify CL-derived TNF as a potent effector of
birinapant mediated anti-
tumor immunity and opportunity for combination
therapy through co-inhibition of immune checkpoints.